On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback